BRPI0720371B8 - métodos para diagnóstico ou monitoramento da progressão de câncer de próstata em um indivíduo e uso in vitro de pelo menos um homeodomínio contendo o fator de transcrição como um biomarcador para câncer de próstata - Google Patents

métodos para diagnóstico ou monitoramento da progressão de câncer de próstata em um indivíduo e uso in vitro de pelo menos um homeodomínio contendo o fator de transcrição como um biomarcador para câncer de próstata

Info

Publication number
BRPI0720371B8
BRPI0720371B8 BRPI0720371A BRPI0720371A BRPI0720371B8 BR PI0720371 B8 BRPI0720371 B8 BR PI0720371B8 BR PI0720371 A BRPI0720371 A BR PI0720371A BR PI0720371 A BRPI0720371 A BR PI0720371A BR PI0720371 B8 BRPI0720371 B8 BR PI0720371B8
Authority
BR
Brazil
Prior art keywords
prostate cancer
biomarker
methods
transcription factor
diagnosing
Prior art date
Application number
BRPI0720371A
Other languages
English (en)
Portuguese (pt)
Inventor
Pandha Hardev
George Leonard Morgan Richard
Original Assignee
The Univ Of Surrey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Univ Of Surrey filed Critical The Univ Of Surrey
Publication of BRPI0720371A2 publication Critical patent/BRPI0720371A2/pt
Publication of BRPI0720371B1 publication Critical patent/BRPI0720371B1/pt
Publication of BRPI0720371B8 publication Critical patent/BRPI0720371B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
BRPI0720371A 2006-12-19 2007-12-19 métodos para diagnóstico ou monitoramento da progressão de câncer de próstata em um indivíduo e uso in vitro de pelo menos um homeodomínio contendo o fator de transcrição como um biomarcador para câncer de próstata BRPI0720371B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0625321.5A GB0625321D0 (en) 2006-12-19 2006-12-19 Cancer biomarker
GB0625321.5 2006-12-19
GBGB0719792.4A GB0719792D0 (en) 2006-12-19 2007-10-10 Cancer biomarkers
GB0719792.4 2007-10-10
PCT/GB2007/004902 WO2008075056A1 (en) 2006-12-19 2007-12-19 Cancer biomarkers

Publications (3)

Publication Number Publication Date
BRPI0720371A2 BRPI0720371A2 (pt) 2013-12-31
BRPI0720371B1 BRPI0720371B1 (pt) 2019-05-28
BRPI0720371B8 true BRPI0720371B8 (pt) 2021-07-27

Family

ID=39265269

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720371A BRPI0720371B8 (pt) 2006-12-19 2007-12-19 métodos para diagnóstico ou monitoramento da progressão de câncer de próstata em um indivíduo e uso in vitro de pelo menos um homeodomínio contendo o fator de transcrição como um biomarcador para câncer de próstata

Country Status (19)

Country Link
US (1) US8460882B2 (OSRAM)
EP (1) EP2115472B1 (OSRAM)
JP (1) JP5683108B2 (OSRAM)
CN (1) CN101675341B (OSRAM)
AU (1) AU2007335999B2 (OSRAM)
BR (1) BRPI0720371B8 (OSRAM)
CA (1) CA2671939C (OSRAM)
CY (1) CY1115178T1 (OSRAM)
DK (1) DK2115472T3 (OSRAM)
ES (1) ES2445185T3 (OSRAM)
GB (2) GB0625321D0 (OSRAM)
IL (1) IL199241A (OSRAM)
MX (1) MX2009006378A (OSRAM)
NZ (1) NZ577548A (OSRAM)
PL (1) PL2115472T3 (OSRAM)
PT (1) PT2115472E (OSRAM)
RU (1) RU2460075C2 (OSRAM)
SI (1) SI2115472T1 (OSRAM)
WO (1) WO2008075056A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461126B2 (en) 2005-10-14 2013-06-11 Phigenix, Inc. Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
DE102006047617B4 (de) 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung basischer (Meth)acrylamide
DE102008017216B4 (de) 2008-04-04 2013-08-14 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden
GB0823445D0 (en) * 2008-12-23 2009-01-28 Univ Surrey Biomarker
DE102009031059A1 (de) 2009-06-30 2011-01-05 Clariant International Ltd. Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen
GB0912190D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
JP2012532621A (ja) * 2009-07-13 2012-12-20 ザ ユニバーシティ オブ サリー 治療ペプチド、ポリペプチド及び核酸配列
GB0912175D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
DE102009042523B4 (de) 2009-09-22 2012-02-16 Clariant International Ltd. Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen
DE102009042522A1 (de) 2009-09-22 2011-04-07 Clariant International Ltd. Kontinuierliches Umesterungsverfahren
GB0921329D0 (en) * 2009-12-04 2010-01-20 Univ Surrey Biomarker
DE102010056565A1 (de) 2010-12-30 2012-07-05 Clariant International Ltd. Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere
US20140106363A1 (en) * 2011-05-12 2014-04-17 Noviogendix Research B.V. Molecular markers in prostate cancer
WO2012152800A1 (en) * 2011-05-12 2012-11-15 Noviogendix Research B.V. Molecular markers in prostate cancer
CN103797120B (zh) * 2011-09-16 2017-04-12 上海长海医院 前列腺癌的生物学标志物、治疗靶点及其用途
JP5990274B2 (ja) * 2011-12-05 2016-09-07 ファイジェニクス インコーポレイテッド 前立腺病態の処置のためのｅｎ２、ｐａｘ２、および／またはｄｅｆｂ１の標的化
WO2014005138A1 (en) * 2012-06-29 2014-01-03 Kerschensteiner Daniel A Colorimetric gelatinase assay
WO2014025961A1 (en) * 2012-08-10 2014-02-13 Analiza, Inc. Methods and devices for analyzing species to determine diseases
WO2014179959A1 (en) * 2013-05-09 2014-11-13 The Procter & Gamble Company Method and system for assessing health condition
WO2016102560A1 (en) * 2014-12-23 2016-06-30 The University Of Surrey Glycosylated biomarker
KR101698654B1 (ko) 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
US11827938B2 (en) * 2015-05-29 2023-11-28 Koninklijke Philips N.V. Methods of prostate cancer prognosis
EP3352777B1 (en) * 2015-09-23 2021-09-15 Centre National De La Recherche Scientifique Engrailed for use in the treatment of dna-damage in a patient suffering from parkinson disease
CN106282347A (zh) * 2016-08-17 2017-01-04 中南大学 HoxC11作为生物标志物在制备肺腺癌的预诊断试剂中的应用
EP3564365B1 (en) 2016-12-28 2023-01-25 Guangzhou Institutes Of Biomedicine And Health Chinese Academy Of Sciences Transdifferentation of b lymphoid cells into t cells
KR101777085B1 (ko) * 2017-02-23 2017-09-11 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
KR101777254B1 (ko) 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
KR101777259B1 (ko) 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
CN107727729A (zh) * 2017-11-22 2018-02-23 南宁科城汇信息科技有限公司 一种oa候选标志物诊断模型的建立方法
CN107894507A (zh) * 2017-11-22 2018-04-10 南宁科城汇信息科技有限公司 一种发现和鉴定肝癌血清差异表达蛋白和验证标志物蛋白方法
KR101923199B1 (ko) 2018-04-25 2018-11-28 주식회사 무진메디 펩스타틴 a를 함유하는 소변 내 en2 진단용 조성물
CN111363817B (zh) * 2018-12-26 2024-02-02 广州康立明生物科技股份有限公司 基于hoxd12基因的肺癌诊断剂及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0996725A1 (en) * 1997-06-27 2000-05-03 Human Genome Sciences, Inc. Human nk-3 related prostate specific gene-1
RU2234942C2 (ru) * 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
JP2002527758A (ja) * 1998-10-19 2002-08-27 ダイアデクスアス・インコーポレーテッド 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法
WO2001092879A1 (en) 2000-05-30 2001-12-06 Danmarks Miljø Undersøgelser An assay method and kit for testing biological material for exposure to stress using biomarkers
JP2004501666A (ja) * 2000-06-30 2004-01-22 エピゲノミクス　アーゲー 薬理ゲノミクスのメチル化状態分析のための方法及び核酸
WO2002022884A2 (en) * 2000-09-12 2002-03-21 Transgenetics Incorporated Microarrayed organization of transcription factor target genes
AU2002249834B2 (en) 2000-12-24 2008-05-22 Iser Lubocki A method for detecting biomarkers
US20040063216A1 (en) 2000-12-24 2004-04-01 Iser Lubocki Method for detecting biomarkers
JP2004529630A (ja) * 2001-03-01 2004-09-30 エピゲノミクス アーゲー 診断および治療目的の遺伝子パネルを遺伝子の発現およびメチル化状態に基づいて開発する方法
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
CA2469089A1 (en) * 2003-07-08 2005-01-08 Institut De Recherches Cliniques De Montreal En-2 gene, disgnostic and therapeutic uses thereof
US20060014301A1 (en) 2004-07-13 2006-01-19 Power3 Medical Products, Inc. Antibody-based system for detection of differential protein expression patterns
EP2284279A1 (en) * 2004-12-02 2011-02-16 Epigenomics AG Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
US9416422B2 (en) 2005-02-18 2016-08-16 Sloan-Kettering Institute For Cancer Research Methods for detecting minimum residual disease

Also Published As

Publication number Publication date
CA2671939C (en) 2017-10-03
AU2007335999A1 (en) 2008-06-26
RU2460075C2 (ru) 2012-08-27
PT2115472E (pt) 2014-02-14
CN101675341B (zh) 2017-08-08
RU2009127774A (ru) 2011-01-27
ES2445185T3 (es) 2014-02-28
PL2115472T3 (pl) 2014-05-30
DK2115472T3 (da) 2014-02-10
US20100093558A1 (en) 2010-04-15
BRPI0720371A2 (pt) 2013-12-31
GB0719792D0 (en) 2007-11-21
WO2008075056A1 (en) 2008-06-26
IL199241A (en) 2014-03-31
MX2009006378A (es) 2009-08-24
CN101675341A (zh) 2010-03-17
CA2671939A1 (en) 2008-06-26
CY1115178T1 (el) 2016-12-14
US8460882B2 (en) 2013-06-11
EP2115472B1 (en) 2013-11-06
GB0625321D0 (en) 2007-01-24
EP2115472A1 (en) 2009-11-11
AU2007335999B2 (en) 2013-09-05
NZ577548A (en) 2012-03-30
JP2010513901A (ja) 2010-04-30
JP5683108B2 (ja) 2015-03-11
SI2115472T1 (sl) 2014-05-30
BRPI0720371B1 (pt) 2019-05-28

Similar Documents

Publication Publication Date Title
BRPI0720371B8 (pt) métodos para diagnóstico ou monitoramento da progressão de câncer de próstata em um indivíduo e uso in vitro de pelo menos um homeodomínio contendo o fator de transcrição como um biomarcador para câncer de próstata
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
WO2012021795A3 (en) Pancreatic cancer biomarkers and uses thereof
WO2014201516A3 (en) Biomarker identification
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
ATE554389T1 (de) Apex als marker für lungenkrebs
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
BR112012029281A2 (pt) anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo
ES2570359T3 (es) Regiones ultraconservadas que codifican ARNnc
MX2014004860A (es) Biomarcadores de cancer de pulmon y usos de los mismos.
WO2008061104A3 (en) Methods and kits for detecting prostate cancer biomarkers
AR066725A1 (es) Prediccion del pronostico para melanoma de cancer
HK1259001A1 (zh) 癌症的预後和诊断方法
WO2009143181A3 (en) Micro-rna profile in human saliva and its use for detection of oral cancer
BR112013011590A2 (pt) método de tratamento de câncer
BR112016002845A2 (pt) composições e métodos para tratar condições associadas ao complemento
GB201207297D0 (en) Analytical methods and arrays for use in the same
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
EP3159695A3 (en) Methods for diagnosing pancreatic cancer
DE602006020544D1 (de) Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
WO2013028807A3 (en) Renal cell carcinoma biomarkers and uses thereof
WO2011074802A3 (ko) 전립선암 진단용 키트 및 진단방법
BR112015010399A2 (pt) método e kit para a determinação de cobre livre no soro

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/05/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2649 DE 13-10-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.